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Condensed abstract: In this meta-analysis of 6 studies including 225 patients with thyroid nodules with 
indeterminate FNAB, FDG-PET proved an excellent discriminator for which patients do not benefit 
from diagnostic surgery as the negative predictive value to rule out thyroid cancer was 96%. 
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Abstract 
Background: Indeterminate results at fine needle aspiration biopsy (FNAB) of thyroid nodules pose a clinical 
dilemma as only 20-30% of the patients suffer from malignancy. Previous studies suggested that the false-
negative ratio of FDG-PET is very low, therefore it might help to identify those who benefit from 
(hemi)thyroidectomy.  
Methods: A systematic search was performed in five databases. After assessment, the studies were analyzed for 
heterogeneity and the extracted data of test characteristics were pooled using a random effects model. Threshold 
effects were examined and publication bias was assessed.  
Results: The query resulted in 239 records, of which 6 studies met our predefined inclusion criteria. The data of 
225 of the 241 described patients could be extracted. There was mild to moderate heterogeneity in study results 
(I2=0.390-0.867). The pooled prevalence of malignancy was 26%. Pooled sensitivity, specificity, positive and 
negative predictive value and accuracy were 95% (95%-confidence interval: 86-99%), 48% (40-56%), 39% (31-
47%), 96% (90-99%) and 60% (53-67%), respectively. Sensitivity increased to 100% for the 164 lesions larger 
than 15mm. There were no evidences of threshold effects or publication bias. Conclusion: A negative FDG-PET 
scan in thyroid nodules larger than 15 mm with indeterminate FNAB excludes thyroid cancer in a pooled 
population of 225 patients. Conversely, a positive FDG-PET does not implicate cancer as approximately half of 
these patients have benign nodules. Therefore, incorporation of FDG-PET in the initial work-up of these patients 
prior to surgery is worth further investigation. 
 
Keywords: Fluorodeoxyglucose F18, Positron-Emission Tomography, Meta-Analysis, Systematic 
Review, Thyroid Nodules, Thyroidectomy.  
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Introduction 
Thyroid cancer is the most common endocrine malignancy. It represents approximately 1% of all 
cancers, corresponding to an incidence of up to 10.2 per 100 000 people per year in the US.1, 2 with 
increasing incidence over the last decades.2, 3 
The most common clinical presentation of thyroid cancer is a thyroid nodule (TN), either 
solitary or (dominant) within a multinodular goiter. Approximately 5-10% of adults have palpable TNs 
and 17-45% have nodules identified by ultrasound.4-6 The majority of these nodules are benign, but 
approximately 5-15% of all palpable thyroid nodules are malignant.5, 7 Fine-needle aspiration biopsy 
(FNAB) is the most important diagnostic test in the initial evaluation of a patient with a TN with a 
high diagnostic accuracy (70-97% in experienced centers). Approximately 70% of the results of 
FNAB are classified as benign, 4% as malignant, 2-10% as insufficient material and the remaining as 
either indeterminate or suspicious (16-24%). Due to similar cytological features, it is particularly 
challenging to distinguish between different types of thyroid neoplasms of the follicular type (i.e. 
follicular thyroid adenoma, follicular thyroid carcinoma (FTC) and follicular type of papillary 
carcinoma). Therefore, patients with indeterminate or suspicious FNAB results have to undergo 
diagnostic hemithyroidectomy to exclude malignancy.7 As only 20-30% of these nodules are 
malignant8, most of the patients are unnecessarily undergoing thyroid surgery, with potential risk for 
irreversible complications.  
Several promising markers (e.g. thyroid peroxidase (TPO), galectin-3, telomerase, RET/PTC, 
p53) have been studied in patients with TNs in order to improve the accuracy of FNAB. Yet none of 
these markers have reached routine clinical use as they have only been documented in a subset of 
tumors.9 Both ultrasonographic and scintigraphic features of TNs have been investigated in the past for 
their diagnostic value in the preoperative diagnostic work-up of patients with thyroid nodules, but 
none of these technique could accurately distinguish between benign and malignant nodules. 
Characterization of tissue using the glucose analogue [18F]-2-fluoro-2-deoxy-D-glucose (FDG) 
together with positron emission tomography (PET) has proven beneficial in diagnostics and follow-up 
of many malignancies.10 The use of FDG-PET/CT in the management of thyroid disease has been 
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limited primarily to the postoperative surveillance of patients with known differentiated thyroid 
carcinoma (postoperative staging for remnant disease and in therapy response assessment5). There is a 
special role for FDG-PET/CT in postoperative surveillance in case thyroglobulin (Tg) is elevated but 
whole-body [131I]-scintigraphy is negative.5 Finally, FDG-PET/CT thyroid incidentalomas are found in 
approximately 1-2% of FDG-PET/CTs and harbor a 14-47% chance of being confirmed malignant11-13 
warranting further investigations.5, 14 Currently, there is no routine place for FDG-PET/CT in the 
work-up of a TN.5 
This systematic review aims to provide an up-to-date summary of the value of FDG-PET/CT 
for the preoperative evaluation of patients with TNs and either indeterminate or repeatedly insufficient 
FNAB. By a systematic literature search and meta-analysis, the false-negative rate of FDG-PET/CT is 
quantified to investigate whether a negative FDG-PET/CT scan can select patients with a low 
suspicion of malignancy in whom surgery therefore can be omitted. 
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Material and Methods 
Literature Search and Study Selection 
A systematic search was performed using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement (Figure 1).15, 16 
The main research question was defined using the PICTS strategy: target Population (including 
previous tests), Index test, Comparator test, Target condition and Study design.17-19 It was formulated 
into a search query containing a combination of Medical Subject Headings (MeSH) or keywords and 
truncated synonyms (Boolean operators). Then, a search using this query was performed November 21 
2010, with the following five search engines, which use partially overlapping databases: PubMed, 
Scopus, the library of the Cochrane Collaborations, OvidSP MEDLINE and OvidSP MEDLINE In 
Process & Other Non-Indexed Citations. Review articles and letters-to-the editor, articles with less 
than 5 patients included and articles written in languages other than English, French, German or Dutch 
were excluded. 
 
Quality Assessment and Data Extraction 
Quality appraisal of retrieved full-text articles were all graded independently by two investigators, for 
quality and applicability by the Quality Assessment tool for Diagnostic Accuracy Studies (QUADAS). 
This widely used tool consists of 14 items that cover patient spectrum, reference standard, disease 
progression bias, verification and review bias, clinical review bias, incorporation bias, test execution, 
study withdrawals and intermediate results.20, 21 Disagreements were resolved by consensus after re-
evaluation of the references. 
Individual patient data were extracted from the approved published articles for all patients 
with indeterminate (follicular or Hürthle cell (oxyphilic, oncocytic) proliferation) or (repeatedly) 
inconclusive FNAB in whom both an FDG-PET and surgery was performed and final 
histopathological diagnosis was available. Heterogeneity in PET acquisition and quantification of 
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FDG-uptake led to the conclusion that between study comparison of quantitative parameters was 
impossible22 and therefore not attempted. Therefore, a positive test result was solely based on visual 
assessment of the PET-scan and defined as “any focal increased uptake in the region of the TN above 
background”. Final histopathological diagnosis served as the Gold Standard outcome parameter. When 
final histopathology showed microcarcinoma (defined as <1 cm in diameter) this was considered a 
coincidental finding in benign disease. Maximum lesion diameter measured on histopathology was 
noted for all patients. As the diameter of the lesions previously described by our group were not 
published23, they were retrieved from the original data. In case of multiple nodules, bias caused by 
FNAB sampling error or spatial mismatch between the nodule and on the FDG-PET was neglected. 
Therefore a patient-based rather than a lesion-by-lesion analysis was performed. 
 
Data Synthesis and Statistical Analysis: 
Agreement in the per-item QUADAS score per reference between the two reviewers was expressed 
using Cohen’s κ-coefficient and was interpreted according to the suggestions of Landis and Koch.24 
The intraclass correlation coefficient (ICC) using a two-way random effects model with a definition of 
absolute agreement was used to quantify agreement for the overall score. 
Heterogeneity of the study populations was assessed by comparing the distribution of possible 
confounders in the included references. Proportions (sex, FNAB results, prevalence of malignancy, 
histology results) were compared between references using either the χ2-statistic or Fisher’s exact test. 
The continuous potential confounders (patient age, tumor diameter) were assessed for (log-)normality 
(histograms, skewness, kurtosis, Shapiro-Wilk). In case of (log-)normality means (±standard 
deviations, SD) and in all other cases medians (with interquartile ranges, IQR) are presented. 
Comparison of (log-)normal distributed variables between references was performed by one-way 
ANOVA followed by Tukeys HSD post-hoc test. In case of violation of normality, Kruskal-Wallis H 
was used as non-parametric equivalent for comparison between multiple independent groups and the 
Mann-Whitney U test for comparison between two independent groups. 
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Extracted data was ordered in 2x2 contingency tables from which disease prevalence and 
diagnostic test characteristics (Sensitivity, Specificity, Positive (PPV) and Negative Predictive Value 
(NPV), Positive (LR+) and Negative Likelihood Ratio (LR-), diagnostic Odds Ratio (dOR) and 
Accuracy (Acc)) could be calculated using the classical equations. To avoid calculation problems by 
having zero values, 0.5 was added to each cell of the respective contingency table as is commonly 
used.25 95-confidence intervals (95-CI) for the proportions were calculated using the β-distribution 
(the exact Clopper-Pearson interval), since the commonly used asymptotic normal approximation only 
holds true for observed frequencies higher than five individual patients.26 
Since sensitivity and specificity are often inversely related because of the threshold effect, 
study heterogeneity in these diagnostic test characteristics was visualized using a summary Receiver 
Operating Characteristic (sROC) curve for which the Area Under the Curve (AUC) was calculated.27, 
28 Other causes of between-study heterogeneity in diagnostic test characteristics were assessed using χ2 
statistics (heterogeneity was defined as p<0.10) and quantified by the inconsistency index (I2, i.e. the 
amount of variability in the results attributable to between-study variation29). A funnel plot of the dOR 
of each study is constructed to provide insight into publication bias.30 Since the dOR is approximately 
log-normally distributed, correlation between the log(dOR) and the standard error of the study effect 
determined by the Kendall τb rank correlation coefficient31 and the Egger statistic32, as a significant 
correlation suggests publication bias. 
Pooled sensitivity and specificity were computed based on individual patient data (i.e. the 
using the sum of the true positive, true negative, false positive and false negative individuals). Ratios 
(LR+, LR- and dOR) were pooled using 3 strategies: (1) pooling individual patient data, which 
assumes negligible heterogeneity, (2) weighted (Mantel-Haenzel) averaging of per-study data, which 
assumes a fixed effect and weights studies by their precision and therefore is less sensitive to (small) 
inaccurate studies with extreme effects and (3) weighted (DerSimonian-Laird) averaging of per-study 
data, which allows a random effects and therefore is less sensitive to study heterogeneity. Data is 
presented in forest plots and τ2 is presented as a value for the between-study variance of the random 
effects model.  
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All analyses were performed using SPSS version 16.0.2. A two tailed p<0.05 was considered 
significant. All meta-analyses (pooling and sROC analysis) are performed using Meta-DiSc version 
1.4.33 
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Results 
Literature Search and Study Selection 
After removal of duplicates, the query resulted in 239 articles of which, after discarding references 
fulfilling the exclusion criteria, 29 references remained (Figure 1). Of these, 20 dealt with “prevalence 
of malignancy in thyroid incidentalomas found on FDG-PET/CT” and 9 with the main search 
question.23, 34-41 
 
Quality assessment 
There was substantial agreement between both reviewers concurring in 104 of 126 QUADAS items 
(κ=0.693, p<0.001). The correlation of absolute overall scores between both reviewers was moderate 
(ICC=0.721, p=0.010). Three references were unsuitable for meta-analysis due to limitation to lesion-
by-lesion analysis35, lack of definition of FDG-PET-positivity and of final histopathological diagnosis 
in each patient39 or being unclear with respect to which and how many patients had indeterminate 
FNAB results.40 In none of the reviewed articles the FDG-PET and histology data were interpreted in 
combination with other clinical data that would be available in practice (QUADAS item 12). Only one 
reference35 described the methodology of the FDG-PET in sufficient detail to permit replication 
(QUADAS item 9) and only one41 mentioned blinding of the pathologist to the FDG-PET findings 
(QUADAS item 11). 
 
Study Heterogeneity 
The selected studies were carried out in Austria (in an endemic goiter area)34, the Netherlands23, 
South-Korea36, Brazil37 and the USA38, 41. Four of the studies were carried out in university hospitals36-
38, 41, one in a general hospital34 and one was a multicentre trial carried out in a university hospital and 
a general hospital23. In all but one study38, all patients had TSH within the normal range. The portion 
of patients with a single thyroid nodule varied from 50% to 100%. Population, in- and exclusion 
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criteria of these 6 studies are described in Table 1. Inclusion criteria varied somewhat among studies, 
mainly concerning nodule size, preselection of patients with nodules with suspect ultrasonographic or 
scintigraphic features.34 
In two studies not all patients could be used for this meta-analysis: 6/43 patient in one study34 
showed papillary thyroid carcinoma (PTC) at FNAB and were reported as positive controls, 10/46 
patients in another study36 refused surgery, therefore no histopathological diagnosis was available. As 
a result, the data of 225 of 241 individual patients were available for pooling. Results of US 
investigation was described for 35% of these. 
Data for age, sex, FNAB results, FDG-PET results and final histopathological diagnosis was 
known on the individual patient level. Patient age, maximum nodule diameter measured histologically 
and FNAB results, all of which are potential confounders causing heterogeneity in study results, were 
significantly different between the six included studies. The fraction of female patients was not 
significantly different (Table 2). 
FDG-PET was performed in all patients at least 17 days post-FNAB23, 36, 37, although 3 studies did 
not mention this interval.34, 38, 41 It was performed 60-70 min after injection of 188-555MBq of FDG 
and visually interpreted by one or two (blinded) experienced observers. A positive FDG-PET was 
defined as any FDG-uptake higher than the background thyroid bed in all but one study38. This study 
added a further restriction that the maximum standardized uptake value (SUVmax) of the lesion had to 
be higher than 2.0 to be considered FDG-PET positive.38 This quantitative restriction was not 
considered in the meta-analysis for the purpose of homogenization of definition of a positive test. 
Therefore patients #5, #13 and #15 in the study of Hales et al.38 were shifted to PET-positive by our 
definition. Another study41 described 4 patients with “incidental” PTC (0.3-17mm in diameter). Due to 
the fact the lesions were found distant from the nodule of interest as seen on US and since the nodule 
of interest was caused by another (benign) thyroid disease the nodule was considered benign. 
The prevalence of malignancy in the pooled population was 25.8% (range 13.6% to 41.7%, 
Fishers Exact=10.7, p=0.055) (Table 3). Of the benign disorders, multinodular goiter was the cause of 
thyroid nodules in 44% (range 15-71%), follicular adenoma in 33% (range 0-52%), Hürthle cell 
adenoma in 9% (range 0-37%), (lymphocytic) thyreoiditis in 4% (range 0-33%) and a combination of 
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benign disorders in 10% (range 0-33%). The distribution of benign causes of thyroid nodules was 
statistically different between studies (Fishers Exact=70.7, p<0.001). Malignant disorders were mainly 
caused by FTC (35%, range 0-73%), PTC (26%, range 0-50%), Hürthle cell carcinoma (5%, range 0-
13%) and anaplastic carcinoma (3%, range 0-20%). The remaining 31% of malignant cases (range 0-
60%) were either a combination of malignant histologies, variants of FTC or PTC or malignancy not 
otherwise specified by the authors. The distribution of malignant causes of thyroid nodules was 
statistically different between studies (Fishers Exact=38.2, p<0.001). 
 
Pooled Data 
The pooled sensitivity of FDG-PET for the detection of cancer was 94.8% (95-CI: 85.6-98.9%), but 
there was moderate though non-significant inconsistency among studies (I2=0.390, χ2df=5=8.2, 
p=0.146). The pooled specificity was 47.9% (95-CI: 40.1-55.8%), but there was a high and significant 
inconsistency between studies (I2=0.867, χ2df=5=37.6, p<0.001) mainly because a specificity of 0% was 
reported in one study36 in which all patients had positive FDG-PET scans (i.e. there were no negative 
cases). We could not find a (methodological) cause and therefore did not exclude this study from 
further analysis. The pooled NPV was 96.4% (95-CI: 89.8-99.2%) and the pooled PPV was 38.7% 
(95-CI: 30.7-47.3%), with an overall accuracy of FDG-PET for determination of thyroid nodule 
malignancy of 60.0% (95-CI: 53.3-66.5%) (Table 3). 
Based on the pooled analysis of individual patient data, the LR+ was 1.82 (95-CI: 1.56-2.13). 
Using the fixed effects the LR+ was 1.56 (95-CI: 1.36-1.80, high heterogeneity: χ2df=5=76.0, p<0.001, 
I2=0.934), but considering the heterogeneity random effects modeling seemed more appropriate. With 
random effects the LR+ was 1.67 (95-CI: 0.98-2.84, τ2=0.39). The LR- could not be computed for one 
study36 since there were no FDG-PET negative cases. Therefore, pooling was based on the remaining 
5 references. Using fixed effects the LR- was 0.19 (95-CI: 0.076-0.46, low heterogeneity: χ2df=4=2.33, 
p=0.676, I2<0.001). With random effects the LR- was 0.24 (95-CI: 0.10-0.59, τ2<0.01) (Figure 2). 
Therefore the pre-FDG-PET probability of malignancy (prevalence) rose from 25.8% to 38.7% for a 
positive FDG-PET (PPV) and decreased to 3.6% in case the FDG-PET was negative (1-NPV). 
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The sROC curve showed no ‘shoulder arm’ plot suggesting no threshold effect (Figure 3), the 
AUC was 0.84 (±0.079). The symmetrical funnel plot of the dOR showed no evidence of publication 
bias (Figure 4), which was confirmed by an insignificant correlation (Kendall τb=0.067, p=0.851, 
Egger’s statistic: t=-0.054, p=0.959). 
In total three of 58 patients with differentiated thyroid carcinoma showed a false-negative 
FDG-PET scan. Patient #1 in Hales et al.38 was diagnosed with a 14 mm PTC, which showed diffuse 
moderate uptake (SUVmax 1.5) similar to the thyroid background FDG-uptake. Patient #1 and #12 in 
Traugott et al.41 both showed a follicular variant PTC of 7 and 9 mm respectively, but no focal 
increase of FDG-uptake was seen in the thyroid gland. These 3 false-negative lesions were 
significantly smaller in diameter than other malignant lesions (median diameter 26mm (IQR: 18-
50mm), Mann-Whitney U: 15.0, p=0.011) as well as all other lesions (median diameter 21mm (IQR: 
15-35mm), Mann-Whitney U: 72.0, p=0.014). Evaluation of the 164 TNs larger than 15 mm therefore 
led to a sensitivity of FDG-PET in detection of thyroid cancer of 100% (95-CI: 92.5-100%), whereas 
specificity remained similar (46.6%, 95-CI: 37.4-56.0%) (Figure 5). 
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Discussion 
In this meta-analysis, FDG-PET was considered positive in 142 of 225 patients (63%) with a thyroid 
nodule with either indeterminate or repeatedly inconclusive cytology of FNAB. When surgery was 
performed consequently, almost 40% of these were confirmed at final histopathology as carcinoma. A 
negative FDG-PET demonstrated malignancy in only 3 of 83 (3.6%) of these individual patients 
without focal FDG-uptake, all having a histological diameter below 1.5 cm. In the clinical work-up for 
patients with larger nodules FDG-PET is considered a useful tool and can reliably exclude T2 
malignancies by a negative FDG-PET. 
We computed that it would require 72 patients with thyroid malignancy all having a positive 
FDG-PET scan to be reasonably confident the true sensitivity is higher than 95% (i.e. the lower level 
of the 2-tailed Clopper-Pearson 95-CI or the solution to 1 − 𝛽!!!! 𝑛 − 𝑥 + 1, 𝑥 ≥ 0.95 with n=x=1 
and α=0.05). Since the prevalence of malignancy in TN in the presented data was 25.8%, at least 276 
patients with TN with indeterminate FNAB should have been included. Up to date, published studies 
have sample sizes much smaller than this number, therefore this comprehensive meta-analysis, was 
undertaken. 
As meta-analyses are prone to error due to factors such as low study quality, study 
inhomogeneity and publication bias these factors were minimized by careful selection and quality 
appraisal of references and description of potential causes of heterogeneity and publication bias. This 
resulted in a pooled LR- of 0.19 (fixed effects) - 0.24 (random effects), indicating that the pre-FDG-
PET probability of malignancy in these patients decreases from 26% (the prevalence) to 6.2% (fixed 
effects) or 7.7% (random effects) after a negative FDG-PET scan. In other words, incorporation of 
FDG-PET in the workup of a TN with indeterminate FNAB rightly saves 27 patients from diagnostic 
surgery at the cost of one patient that is unjustifiably delayed surgical treatment (80/225 patients 
would rightly not be operated upon when incorporating FDG-PET in the work-up of a TN (true 
negatives), however 3/225 patients would faultily not be operated upon due to a false negative result: 
80/3≈27/1). The number of false negatives can be decreased by only taking lesions larger than 15mm 
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by pathology in diameter into consideration. This might be explained as a consequence of the partial-
volume effect due to the limited spatial resolution (>~6mm) of used PET scanners. 
The total costs for FDG-PET in The Netherlands currently is approximately €1,400 (in the US, 
for comparison the reimbursement rate currently is approximately $1050) and the treatment costs are 
mainly driven by the costs of surgery and hospitalization, with mean costs per patient amounting to 
€3,311 in benign and €5,228 in malignant cases, without considering additional-treatment costs, 
economic costs or indirect costs.42, 43 In the pooled population in this meta-analysis, surgery in all 
patients would result in an average cost per patients of €3,805 without the use of FDG-PET and € 
3958 with the use of FDG-PET in the Netherlands (approximately €3,608 in based on the 
reimbursement rate in the US). Thus, both scenarios generate similar direct costs, while additional-
treatment costs, economic costs or indirect costs of futile surgery are not even considered. For this 
computation, we did not consider extra costs for the 1.3% false-negative FDG-PET scans. 
However, there remain other reasons to consider surgery despite this cost-effectiveness: 
mechanical or cosmetic concerns or mere reassurance. Nonetheless, as in larger lesions the 
complication rates can be higher (due to extension towards the large vessels, trachea or recurrent 
laryngeal nerve) these patients might benefit most of reassurance by a true-negative PET. However in 
patients with small lesions (<15mm) the value of FDG-PET should be weighed against the 
disadvantage of the risk of a false-negative result. When renouncing surgery in these patients, follow-
up remains warranted. 
A limitation of this meta-analysis is that different studies used different definitions of FDG-
PET-positivity. For example, Hales et al.38 required a threshold SUVmax of 2.0 for a positive test. It 
was tried to use exactly the same definition for FDG-PET-positivity for each reference. However, 
since the FDG-PET scans were not examined centrally, still some inhomogeneity due to inter-observer 
variability in interpretation of these images remain. Another limitation is the definition of malignancy: 
some excluded incidentally found papillary microcarcinomas from participation in the study36, 37, 
others even considered malignant lesions found distant from the (benign) index nodule.41 Of the four 
lesions of latter category (0.3, 4, 8 and 17mm PTC), two were FDG-PET negative and could therefore 
also be considered false-negative rather than true-negative scans. This would have increased the total 
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number of false negative scans to 5 and therefore decreased the pooled sensitivity from 95% (95-CI: 
86-99%) to 92% (95-CI: 82-97%). A final limitation is concerning the population heterogeneity, 
particularly the vast variation in prevalence of malignancy (14-42%) in different parts of the world 
with both endemic goiter and iodine-sufficient areas. 
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Conclusions 
This comprehensive systematic review and meta-analysis of the literature showed that in patients with 
TN with indeterminate FNAB, a negative FDG-PET scan improves diagnostic accuracy, particularly 
in patients with lesions larger than 15 mm. All false-negatives FDG-PET cases were lesions smaller 
than 15 mm (i.e. T1 tumors). A positive FDG-PET increases the chance of malignancy from 25.8% to 
38.7% in these patients. Further prospective series are ongoing and will ultimately reveal the value of 
FDG-PET in the diagnostic evaluation of thyroid nodules to confirm these findings. 
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Tables 
 
Ref.: First author 
(year): 
City / 
country: 
Hospital 
type: 
Inclusion criteria: Exclusion criteria: TSH: STN: Remarks: 
34 Kresnik 
(2003) 
Klagenfurt, 
Austria 
G - All patients with TN 
- hypoechogenic or no uptake on scintigraphy 
- FNAB: follicular or Hürthle cell proliferation 
- scheduled for surgery 
- Autonomous goiter Normal in all 24/43 Endemic 
goiter area 
23 De Geus-Oei 
(2006) 
Nijmegen, 
the 
Netherlands 
U&G - palpable TN 
- inconclusive FNAB 
- scheduled for hemithyroidectomy 
- DM 
- pregnancy 
Normal in all 44/44 Multicentre 
trial 
36 Kim (2007) Seoul, 
South-Korea 
U - TN larger than 1 cm 
- FNAB: follicular proliferation 
 Normal in all 32/46  
37 Sebastianes 
(2007) 
São Paulo, 
Brazil 
U - FNAB: indeterminate 
- scheduled for (hemi)thyroidectomy 
- uncontrollable DM 
- other malignancies 
- pregnancy 
- abnormal TSH 
Normal in all 21/42  
38 Hales (2008) Oklahoma 
City (OK), 
USA 
U - All patients with TN 
- FNAB: indeterminate 
- pregnancy 
- breastfeeding 
- prior H&N surgery 
- >181 kg bodyweight 
? 8/15  
41 Traugott 
(2010) 
St Louis 
(MO), 
USA 
U - Adults with TN or dominant TN 
- palpable or >1cm on US 
- scheduled for surgery 
- prior neck surgery 
- prior radiotherapy 
Normal in all 51/51 Interim 
Analysis 
Table 1: Characteristics of the patient population included in the studies selected for this meta-analysis. DM: Diabetes Mellitus, FNAB: Fine Needle 
Aspiration Biopsy; G: General hospital; H&N: Head and Neck; STN: Single Thyroid Nodule; U: University Hospital; US: Ultrasonography. 
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Ref.: First author 
(year): 
N Female 
[%]: 
Mean age 
[yr]: (±SD)  
Median hist. 
lesion 
diameter 
[mm]: 
(range)  
FNAB: 
Follicular 
proliferation: 
Hürthle cell 
proliferation: 
Combination: Repetitively 
inconclusive: 
Indeterminate 
NOS: 
34 Kresnik 
(2003)* 
37 78% 55.1 
(±13.8) 
16 
(6-80) 
65% 30% - 5% - 
23 De Geus-Oei 
(2006) 
44 93% 48.5 
(±13.8) 
30# 
(3-55) 
75% 9% 11% 5% - 
36 Kim  
(2007)* 
36 86% 44.2 
(±13.1) 
25 
(10-90) 
100% - - - - 
37 Sebastianes 
(2007) 
42 90% 45.3 
(±16.3) 
28 
(4-85) 
- - - - 100% 
38 Hales 
(2008) 
15 93% 47.5 
(±14.9) 
25 
(1-60) 
80% 13% 7% - - 
41 Traugott 
(2010) 
51 80% 49.6 
(±10.6) 
15 
(5-50)¶ 
69% 10% - - 21% 
Test for between studies 
differences 
p=0.292† p=0.012‡ p<0.001** p<0.001† 
Total 225 86% 48.5 (±13.9) 20 (15-35) 62% 10% 3% 2% 23% 
Table 2: Clinical characteristics of the patients included in the meta-analysis (extracted data). FNAB: Fine Needle Aspiration Biopsy; Hist.: histology; 
SD: standard deviation; NOS: Not Otherwise Specified; *Presented data varies from published data: not all patients used for publications could be used for 
meta-analysis; #Lesion size was unavailable in 9 lesions; ¶ Lesion size was unavailable in 1 lesion; †Computed using Fisher’s Exact (FE) test; ‡Computed 
using one-way ANOVA, difference caused by older patients in study of Kresnik (2003)34 compared to Kim (2007)36 and Sebastianes (2007)37 (Tukey HSD, 
p=0.010 and p=0.020, respectively); **Computed using Kruskal-Wallis H. 
 
  
Page 22 of 24 
 
Ref.: First Author 
(year): 
TP TN FP FN Prev Se Sp NPV PPV Acc 
34 Kresnik 
(2003)* 
10 15 12 0 27.0% 
[13.8-44.1%] 
100% 
[69.2-100%] 
55.6% 
[35.3-74.5%] 
100% 
[78.2-100%] 
45.5% 
[24.4-67.8%] 
67.6% 
[50.2-82.0%] 
23 De Geus-Oei 
(2006) 
6 25 13 0 13.6% 
[5.2-27.4%] 
100% 
[54.1-100%] 
65.8% 
[48.6-80.4%] 
100% 
[86.3-100%] 
31.6% 
[12.6-56.6%] 
70.5% 
[54.8-83.2%] 
36 Kim  
(2007)* 
15 0 21 0 41.7% 
[25.5-59.2%] 
100% 
[78.2-100%] 
0% 
[0-16.1%] 
NaN 
 
41.7% 
[25.5-59.2%] 
41.7% 
[25.5-59.2%] 
37 Sebastianes 
(2007) 
11 12 19 0 26.2% 
[13.9-42.0%] 
100% 
[71.5-100%] 
38.7% 
[21.8-57.8%] 
100% 
[73.5-100%] 
36.7% 
[19.9-56.1%] 
54.8% 
[38.7-70.2%] 
38 Hales 
(2008) 
5 3 6 1 40.0% 
[16.3-67.7%] 
83.3% 
[35.9-99.6%] 
33.3% 
[7.5-70.1%] 
75.0% 
[19.4-99.4%] 
45.5% 
[16.7-76.6%] 
53.3% 
[26.6-78.7%] 
41 Traugott 
(2010) 
8 25 16 2 19.6% 
[9.8-33.1%] 
80.0% 
[44.4-97.5%] 
61.0% 
[44.5-75.8%] 
92.6% 
[75.7-99.1%] 
33.3% 
[15.6-55.3%] 
64.7% 
[50.1-77.6%] 
Pooled 55 80 87 3 25.8% 
[20.2-32.0%] 
94.8% 
[85.6-98.9%] 
47.9% 
[40.1-55.8%] 
96.4% 
[89.9-99.2%] 
38.7% 
[30.7-47.3%] 
60.0% 
[53.3-66.5%] 
Table 3: Test characteristics of FDG-PET [with 95-confidence interval] for detection of malignancy in TN with indeterminate FNAB according to 
references. Acc: accuracy; FN: false negatives; FP: false positives; NaN: not a number; NPV: negative predictive value; TN: true negatives; TP: true 
positives; PPV: positive predictive value; Prev: cancer prevalence; Se: sensitivity; Sp: specificity 
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Figure Captions 
Figure 1: Flowchart of selection of articles. FDG: [18F]-2-fluoro-2-deoxy-D-glucose; FNAB: Fine-
Needle Aspiration Biopsy; MeSH: Medical Subject Heading; PET/CT: Positron Emission 
Tomography / Computed Tomography; PICTS: target Population, Index test, Comparator test, Target 
condition and Study design; RCT: Randomized Controlled Trial; TN: Thyroid Nodule; * marks 
truncation. 
 
Figure 2: Forest plots of sensitivity, specificity, positive and negative likelihood ratio with 
corresponding 95-confidence intervals of FDG-PET in detection of malignancy in TN with 
indeterminate FNAB. Sensitivity and specificity are pooled using individual patient data. The 
likelihood ratios are pooled using either fixed effects (FE) or random effects (RE) modeling. The 
dashed lines represent the pooled effects. The dotted lines represent a likelihood ratio of 1 (i.e. no 
change in likelihood). 
 
Figure 3: Summary Receiver Operating Characteristic (sROC) curve of sensitivity versus 1-
specificity of FDG-PET in detection of malignancy in TN with indeterminate FNAB with 
corresponding boundaries of the 95-confidence interval. There are no signs of threshold effects. The 
area under the curve is 0.84 (±0.079). 
 
Figure 4: Funnel plot of the diagnostic Odds Ratios (dOR) of included references. The solid vertical 
line denotes the pooled dOR and the dashed lines the 95% confidence intervals (95-CI). The standard 
error (SE) of de dOR as well as the pooled dOR was calculated using Mantel-Haenzels weighing 
(fixed effects, FE). Symmetric distribution of references can be seen. No correlation could be detected 
between loge(dOR) and SE(loge(dOR)) as reflected by Kendall τb=0.067 (p=0.851), therefore there is 
no evidence for publication bias. 
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Figure 5: Dependency of sensitivity (Se) and specificity (Sp) with 95-confidence intervals of FDG-
PET in detection of malignancy in TN with indeterminate FNAB. n: the number of patients for which 
the diagnostic test characteristics are computed. 
 





